cannabinomics (n.) | căn‘ • nə • bi • nom • ics; căn • nă‘ • bi • nom • iks | (1) Management of cannabis; (2) Rules, customs, or laws governing cannabis management; cannabis policy; (3) Natural laws pertaining to cannabis; cannabis science; (4) Implied: treatment of cannabis as a commodity or resource; (5) Connotatively and implicitly, the economics of cannabis; (6) More broadly, the language or vocabulary through which public conversation regarding rational and responsible management of cannabis becomes possible.

From medical renaissance to revolution, from drug war prohibition to public health, from economic reefer madness to recovery—trajectories in public policy are converging toward regulation and economic integration of the herbal cannabis trade. “Americans are by and large ready for this change now but haven’t had the vocabulary to articulate it,” writes Cannabinomics author Christopher Glenn Fichtner, M.D., a psychiatrist and former state mental health director.

Cannabinomics is not a medical handbook, a drug war treatise, or an economic model but rather a work of patient and public policy advocacy. It looks at real-world medical cases, recent trends in successful policy reform, drug war costs, and the potential economic benefits of cannabis change. Cannabinomics calls for a stakeholder-inclusive regulatory process to help America take ownership of this homegrown commodity and facilitate system learning that could help solve larger global drug war problems.

“Cannabinomics is …

… a powerful and scholarly read to bring to the marijuana debate.” Midwest Book Review | Oregon, Wisconsin

… a powerful argument for reforming cannabis policy … a remarkable book, destined to take its place among the more influential scholarly works on cannabis reform.” Culture Magazine | Corona, California

… a humane, thoughtful, and powerful look at how we as a society can better deal with one of our most popular–and least harmful–substances … a very important work indeed.” Drug War Chronicle | Washington, D.C.

… an incisive administrative and clinical analysis that dissects the failure of American drug policy and charts a bright future for medicinal cannabis.” David Bearman, M.D., Founding Board Member and Vice President, American Academy of Cannabinoid Medicine; Author of Demons, Discrimination and Dollars: A Brief History of the Origins of American Drug Policy (Prosperity Press, 2008)

… a must read for anyone interested in cannabis policy reform. A highly experienced psychiatrist has put the facts, myths and opinions that swirl around drug policy reform into one comprehensive book that allows the reader to see through the fog of the drug war rhetoric and partisan propaganda.” David G. Ostrow, M.D., Ph.D., Senior Research Associate, Ogburn-Stouffer Center for Organizational Research, NORC at the University of Chicago; Founding Principle Investigator and Chair, Behavioral Working Group of the Multicenter AIDS Cohort Study; Chair, Scientific Advisory Board, Americans for Safe Access